Literature DB >> 17707198

Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site.

Shreerang Bhide1, Catherine Clark, Kevin Harrington, Christopher M Nutting.   

Abstract

Head and neck squamous cell carcinoma with occult primary site represents a controversial clinical problem. Conventional total mucosal irradiation (TMI) maximizes local control, but at the expense of xerostomia. IMRT has been shown to spare salivary tissue in head and cancer patients. This study has been performed to investigate the potential of IMRT to perform nodal and TMI and also allow parotid gland sparing in this patient group. Conventional radiotherapy (CRT) and IMRT plans were produced for six patients to treat the ipsilateral (involved) post-operative neck (PTV1) and the un-operated contralateral neck and mucosal axis (PTV2). Plans were produced with and without the inclusion of nasopharynx in the PTV2. The potential to improve target coverage and spare the parotid glands was investigated for the IMRT plans. There was no significant difference in the mean doses to the PTV1 using CRT and IMRT (59.7 and 60.0 respectively, p = 0.5). The maximum doses to PTV1 and PTV2 were lower for the IMRT technique as compared to CRT (P = 0.008 and P < 0.0001), respectively, and the minimum doses to PTV1 and PTV2 were significantly higher for IMRT as compared to CRT (P = 0.001 and P = 0.001), respectively, illustrating better dose homogeneity with IMRT. The mean dose to the parotid gland contralateral to PTV1 was significantly lower for IMRT (23.21 +/- 0.7) as compared to CRT (50.5 +/- 5.8) (P < 0.0001). There was a significant difference in parotid dose between plans with and without the inclusion of the nasopharynx. IMRT offers improved dose homogeneity in PTV1 and PTV2 and allows for parotid sparing.

Entities:  

Mesh:

Year:  2007        PMID: 17707198     DOI: 10.1016/j.meddos.2007.01.002

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  4 in total

Review 1.  Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers.

Authors:  S A Bhide; K L Newbold; K J Harrington; C M Nutting
Journal:  Br J Radiol       Date:  2012-05       Impact factor: 3.039

2.  Clinical challenges in the implementation of a tomotherapy service for head and neck cancer patients in a regional UK radiotherapy centre.

Authors:  S Chatterjee; J H Mott; G Smyth; S Dickson; W Dobrowsky; C G Kelly
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

3.  Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.

Authors:  Jen Y Lee; Isaac Garcia-Murillas; Rosalind J Cutts; David Gonzalez De Castro; Lorna Grove; Tara Hurley; Fuqiang Wang; Christopher Nutting; Katie Newbold; Kevin Harrington; Nicholas Turner; Shreerang Bhide
Journal:  Br J Cancer       Date:  2017-08-15       Impact factor: 7.640

4.  Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.

Authors:  S A Bhide; K Thway; J Lee; K Wong; P Clarke; K L Newbold; C M Nutting; K J Harrington
Journal:  Br J Cancer       Date:  2016-09-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.